Based on the above, Tdp1 is considered as one of the factors of tumor resistance to therapy with Top1 inhibitors and as a suitable target for accompanying therapy, designed to increase the effectiveness of the main therapy with Top1 inhibitors, including topotecan [11]. Here, TDP1 is linked to neoplasm.